DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA361863
Title:
Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin.
Descriptive Note:
Annual rept. 23 Sep 97-22 Sep 98
Corporate Author:
M D ANDERSON CANCER CENTER HOUSTON TX
Report Date:
1998-10-01
Pagination or Media Count:
7.0
Abstract:
Nine patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 14 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50 of patients. No antitumor responses were seen.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE